Price went up $50 this month with no warning - switching vendors — looking for input

jim_asheville said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

zoe_NC said:

Right, and one flattering data point from a group buy is not consistency.

Thank you for spelling out the reasoning rather than just the conclusion. Taking it to my next appointment.

jim_asheville said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

I disagree that testing history is decisive. It tells you what a supplier did when they were being watched. Continuity of behaviour under stress — a late shipment, a failed test, a complaint — is more predictive than any run of good results.

JenPlateau said:

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

JenPlateau said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. No action needed from anybody.